PHOENIX — Although challenges remain, remote digital health practices can be implemented for most aspects of asthma evaluation and management, according to a speaker at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

Presenting the 24th year of the Elliot F. Ellis Memorial Lectureship during the meeting’s presidential plenary session, Andrew Liu, MD, FAAAAI, director of the Airway Inflammation, Resilience & the Environment (AIRE) Program, co-director of the Asthma Clinical Research Center and member of The Breathing Institute in the section of pediatric pulmonary and sleep medicine at Children’s Hospital Colorado, as well as professor of pediatrics at University of Colorado Denver School of Medicine, discussed how well technology and digital health can help clinicians with the evaluation and management of patients with difficult-to-treat asthma.

“What happened in the start of the pandemic is a good example for all of us,” Liu said. “Many of us got really familiar with digital health tools quickly as we had to pivot to telehealth.

“I remember in that first week of telehealth implementation, the physician in charge of doing this for our section said, ‘It’s like flying a plane while you’re building it.’ And yet she did it, and we’re doing it, and we know that digital tech has been absolutely essential to pandemic health care,” he added.

Patient-specific interventions

A number of studies have shown a substantial benefit in adherence, improvement in asthma impairment and reduction in health care utilization with a digital health intervention that incorporates patient feedback, according to Liu.

“Digital health interventions that seem to benefit patients most are the ones that are patient specific and provide patient feedback,” he said.

To provide an example of what such an intervention looks like, Liu described a study by Mosnaim and colleagues, in which 100 participants with uncontrolled asthma were randomly assigned to a treatment group that received reminders and feedback on inhaled corticosteroid (ICS) and short-acting beta2-agonists (SABAs) use via a smartphone app and clinician phone calls, or a control group without feedback.

“They had inhaler sensors for their controller medication and their rescue albuterol,” Liu said. “The patient-feedback intervention takes that information, alerts them if they miss doses of their controller and it also engages clinician feedback for support of adherence to the controller medication.”

Over the 3 months of the study, results showed a significant 19% increase in the percentage of SABA-free days in the treatment group, compared with a nonsignificant 6% increase in the control group (P = .04). Also, adherence to ICS was retained in the treatment group but decreased in the control group (P < .01).

“It appears that digital health interventions are most effective when they provide patients feedback and link back to us as providers,” Liu said.

AIRE experiences

The AIRE Program at Children’s Hospital Colorado and University of Colorado School of Medicine is a collaborative clinical research group for difficult asthma in children that “functions like a clinical practice lab,” Liu said.

“The AIRE group is facile in digital life, and they really bring that to our relationships with our patients, our study participants and their families,” Liu said. “They’ve been able to do that during the pandemic to keep our science moving forward. I’d like to think that what they’re doing is developing better tools for our current and future practices.”

What they’ve learned during the pandemic may have application to clinical practices, Liu added.

For instance, clinical research studies that continued throughout the pandemic using remote practices employed app-based virtual video visits; digital remote questionnaires and consent-assent forms; app-based daily symptoms dairies; home spirometry; inhaler sensers; and biospecimen collection from the nose, blood, stool and environment.

The HEROS COVID-19 surveillance study sponsored by NIAID was in the field completely remotely within 6 weeks of the start of the pandemic, Liu said. Nasal swab collections occurred every 2 weeks for more than 360,000 samples collected, with 94% of samples meeting acceptability criteria for detecting respiratory virus.

The AIRE lab group also has focused on the ability to conduct environmental sampling remotely, beyond using community-level information from EPA monitors, and pollen levels and outdoor mold levels from the AAAAI-sponsored National Allergy Bureau.

“At the start of the pandemic, we were conducting home inspections and we pivoted to home virtual tours,” Liu said. “We continued to collect dust samples but had them collected remotely to look at home allergens and microbes. There are ways that we can assess home environments for ambient pollution exposures, either indoors or outdoors. Urine can provide us information about toxin exposures like tobacco smoke, and we can get information on respiratory viruses from nasal swabs.”

The AIRE group also has been interested in assessing an individual’s breathing zone — the area from forehead to elbows — using wearable monitors that can assess personal exposure to particulate matter, ozone and nitrogen dioxide levels.

“Virtual visits can’t capture it all, but families and patients took to it better than we thought,” Liu said. “They appreciate the greater flexibility in scheduling and time savings by doing things at home. This allowed some to participate in our research who may not have been able to otherwise. Some also felt more comfortable with going to consent/assent at home, so they could take more time and ask questions.”

The home-based approach represents a shift in responsibility for some of these tasks, such as nasal swabs and dust collection, moving from the provider to the patient.

“We used to do it, now they have to do it,” Liu said. “So that means our partnership with our participants and their families has to be stronger. When we share with them a visualization of their exposure activity location, that’s that kind of personalized feedback that they love.”

Detecting imminent exacerbations

Liu also discussed the possibility of remote patient monitoring to detect beginning signs of an asthma exacerbation.

Data from Covar and colleagues of the PACT study revealed that measures of daily cough/wheeze, rescue albuterol and morning peak flows all significantly changed within 2 days of asthma exacerbations.

“That’s important, because that gives enough time to address it with an oral corticosteroid course, which can improve things in a hurry,” Liu said. “But it’s also important to know that the positive-predictive value for any one of these signals was poor, and the combination of the signals was better, but still not that strong.”

Reporting each of these signals daily can also be hard to maintain for “relatively rare events,” Liu added.

“I’d like to believe that early detection of imminent exacerbation is an important and worthy goal, and remote patient monitoring is likely to get us there,” he said. He added that monitors and apps that detect cough and wheeze are improving, as are activity limitation wearable monitors, in addition to the rescue albuterol inhaler sensors, home pulse oximetry measurers, and other widely available smartphone and app-based platforms.

“The know-how is there to figure out what signals matter most, and to figure out how to combine them and how to interpret them for a highly active signal on predicting imminent exacerbations,” Liu said.

“The potential is high for digital health and remote patient monitoring for difficult asthma, and there is hope for a better future,” he added.

The post Potential is high’ for remote patient monitoring in difficult-to-control asthma appeared first on mTelehealth.

The post wheezo Owner’s Manual – v1.0 – 2022 appeared first on mTelehealth.

The post wheezo Quick Start Guide – v1.0 – 2022 appeared first on mTelehealth.

• Respiri has teamed up with mTelehealth to provide customers with the Wheezo device for evaluation, testing and pilot programs, which are considered the first steps towards seeking reimbursement for the device
• mTelehealth placed a second order for additional Wheezo devices, representing revenues of around US$24,000 (around A$33,600) on top of the US$150,000 (A$210,000) order received in December 2021
• The initiative by mTelehealth is expected to educate senior medical decision makers on the benefits of Wheezo, which is hoped to increase adoption of the device by mTelehealth customers and result in monthly subscriptions
• Respiri is up 6.12 per cent, trading at 5.2 cents at 11:30 am AEDT

eHealth company, Respiri (RSH) has secured a second order for Wheezo from mTelehealth.

Developed in Australia, the Wheezo device analyses breath sounds for wheeze to assist patients with managing their asthma by tracking symptoms, triggers and medication use.

Respiri has teamed up with mTelehealth to provide customers with the Wheezo device for evaluation, testing, and pilot programs, which are considered the first steps towards seeking reimbursement for the device.

To do so, mTelehealth has placed a second order for additional Wheezo devices, representing revenues of around US$24,000 (around A$33,600) on top of the US$150,000 (A$210,000) order received in December 2021.

The initiative by mTelehealth is expected to educate senior medical decision-makers on the benefits of Wheezo, which is hoped to increase adoption of the device by mTelehealth customers and result in monthly subscriptions.

The devices are set to be air freighted immediately to key decision-makers within mTelehealth’s targeted customer base. This will enable a critical review, testing and evaluation required to expedite the piloting of Wheezo.

Respiri says these are considered the first and most difficult steps in seeking to secure reimbursement for Wheezo RPM services and inclusion of Wheezo in management protocols.

Over 600 customers have been targeted, with many of them already requesting Wheezo devices.

“Our partnership with mTelehealth has developed quickly with mTelehealth and the progress they have made with customers in only two months of customer engagement has exceeded all our expectations,” said CEO and Managing Director of Respiri, Marjan Mikel.

“This is a key step in seeking to get reimbursed Wheezo devices into the hands of patients that need it.”

Respiri was up 6.12 percent, trading at 5.2 cents at 11:30 am AEDT.

The post Respiri (RSH) secures second order from mTeleHealth appeared first on mTelehealth.

• mTelehealth to provide paying customers with devices for evaluation, testing and pilot programs, the first steps in seeking to secure reimbursement for wheezo®.

• Targeted senior medical decision makers from over 600 of mTelehealth target customers will be provided with wheezo® devices to allow for internal review, testing and pilot programs.

• The institutions targeted are Health Management Organisations (HMOs/Payors) and Health System with 1,000+ total beds and a minimum $1B in revenue that fund the delivery of reimbursed Remote Patient Monitoring (RPM), Telehealth and Chronic Care Management (CCM) to patients across the USA.

• These customers provide health insurance and care to 128 million Americans across the entire country which equates to about 19 million asthma and Chronic Obstructive Pulmonary Disorder (COPD) patients.

• mTelehealth is a premier provider of RPM services based in Florida

Respiri Limited (ASX:RSH)(“Respiri” or the “Company”), an eHealth SaaS Company supporting respiratory health management is pleased to announce that it has been working with our first partner mTelehealth to undertake action to convert the high levels of interests expressed in the wheezo® RPM solution. As a result, mTelehealth has placed a second order for additional wheezo® devices representing revenues of approximately US$24k on top of the US$150K order received on 23rd December 2021 as part of the signed agreement with mTelehealth as announced to ASX1. This additional order is not considered to be of a material financial nature to the Company. However, this strategic initiative by mTelehealth is expected to educate senior medical decision makers on the benefits of wheezo®, which in turn may result in increased adoption of the device by mTeleheath customers and associated monthly subscriptions, although an estimate of this potential revenue to Respiri cannot be reliably estimated, given future sales are subject to internal review, testing and pilot study outcomes.

Devices will be immediately air freighted and will be provided by mTelehealth to key decision-makers within their targeted customers base to allow for the critical review, testing and evaluation required to expedite the piloting of wheezo® which are the first and most difficult steps in seeking to secure reimbursement for wheezo® RPM services and inclusion of wheezo® in management protocols.

The over 600 customers have been targeted with many of them already requesting wheezo® devices following negotiations already had. The customers provide health insurance cover and healthcare delivery for approximately 128 million Americans across the country and roughly 19 million with asthma and COPD suffer based on local
epidemiology. These customers are broad from progressive smaller payor groups typically insuring 500,000 lives to large premier organizations insuring upwards of 4 million lives and all HMO types have expressed interest in evaluating the wheezo® RPM solution the first critical step to reimbursement approval.

CEO and Managing Director of Respiri, Mr. Marjan Mikel said “Our partnership with mTelehealth has developed quickly with mTelehealth and the progress they have made with customers in only 2 months of customer engagement has exceeded all our expectations. This mTelehealth funded initiative to engage with decision-makers and expedite the payor reimbursement approval process speaks volumes for the relationship Marc and his team have developed over 11 years of business. This is a key step in seeking to get reimbursed wheezo® devices into the hands of patients that need it.”

President and CEO of mTelehealth, Mr. Marc Poulshock said “We have seen an unprecedented positive response to our customer engagement activities to wheezo® and this acted as a catalyst for our investment in accelerating wheezo® evaluation with our customers. Things normally take time to change in the US health market but these
rules seem to not apply to wheezo® which we are pleased about.”

RPM is the use of digital technologies deployed in the collection and analysis of patient physiologic data that are used to develop and manage a treatment plan related to a chronic and/or acute health illness or condition. RPM systems improve patient health and device compliance, which leads to a reduction in hospital admissions and reduced healthcare costs. In parallel, RPM generates new revenue streams for healthcare providers while improving patient care and associated medical information outside the clinic for evaluation and management purposes.

The overall RPM market is expected to show annual growth exceeding 30% to 2026 to US$85 billion, driven by the increase in the occurrence of chronic diseases (including asthma), demand for wireless and portable systems, the presence of sophisticated reimbursement structures, and a move to more cost-effective medical expenditure.

For further information, investors and media please contact:
Mr. Marjan Mikel
CEO & Managing Director
Respiri Limited
P: +61 408 462 873
E: marjan@respiri.co

Mr. Nicholas Smedley
Executive Chairman
Respiri Limited
P: +61 447 074 160
E: nicholas@respiri.co

This ASX announcement dated 4 February 2022 has been authorized for release by the Board of Directors of Respiri Limited.

About Respiri Limited

Respiri is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo®, Respiri’s innovative technology, comprises an eHealth app combined with a simple, easy to use, handheld device. wheezo® is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians and other health care professionals.

Respiri’s mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respiri Limited’s operations are based in Melbourne, Australia.

For additional information about Respiri and its products, please visit www.respiri.co

About wheezo®

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo® device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use, and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

For further information about wheezo®, follow the online link https://wheezo.com

wheezo® is a registered trademark of Respiri Limited.

About mTelehealth

mTelehealth, LLC, founded in 2010 and based in Delray Beach, FL, United States, is a premier provider of Remote Patient Monitoring (RPM), Remote Therapeutic Monitoring (RTM), Telemedicine, Chronic Care Management (CCM), Virtual Exam, Video Visit, and related Telehealth solutions. mTelehealth’s Remote Health Monitoring System, Powered by a TouchAway™, provides a complete solution to remotely collect, store, and report timely and accurate health information anywhere. The company connect patients with their families and care providers through an easy-to-use, affordable, remote health monitoring kit. For more information about mTelehealth, please visit our website: https://mtelehealth.com.

Forward-Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Respiri current expectations, estimates, and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavor of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respiri only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

The post Respiri secures a second order from United States Remote Patient Monitoring partner mTelehealth appeared first on mTelehealth.

Paediatric Respiratory Reviews

Available online 17 January 2022In Press, Journal Pre-proofWhat are Journal Pre-proof articles?

ReviewA scoping review of mHealth monitoring of pediatric bronchial asthma before and during COVID-19 pandemic

Author links open overlay panelNurlanDauletbaev^abcdS.Zoe Oftring^eWidedAkik^fLukasMichaelis-Braun^aJuliaKorel^aLarry C.Lands^bcSusanneWaldmann^gBeate S.Müller^hMichaelDreherⁱGernotRohde^jClaus F.Vogelmeier^aSebastianKuhn^eaDepartment of Internal, Respiratory and Critical Care Medicine, Philipps University of Marburg, Marburg, Germany (Member of the German Center for Lung Research (DZL)), Germany^bDepartment of Pediatrics, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada^cThe Research Institute of McGill University Health Centre, Montreal, QC, Canada^dal-Farabi Kazakh National University, Almaty, Kazakhstan^eDepartment of Digital Medicine, Medical Faculty OWL, Bielefeld University, Bielefeld, Germany^fDivision of Experimental Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada^gCentral Medical Library, Philipps University of Marburg, Marburg, Germany^hInstitute of General Practice, Goethe-University Frankfurt, Frankfurt am Main, GermanyⁱDepartment of Pneumology and Intensive Care Medicine, University Hospital Aachen, Aachen, Germany^jMedical Clinic 1, Department of Respiratory Medicine, University Hospital Frankfurt, Frankfurt am Main, Germany

Received 29 December 2021, Accepted 10 January 2022, Available online 17 January 2022.Show lessAdd to MendeleyShareCitehttps://doi.org/10.1016/j.prrv.2022.01.002Get rights and content

Abstract

Mobile (m) Health technology is well-suited for Remote Patient Monitoring (RPM) in a patient’s habitual environment. In recent years there have been fast-paced developments in mHealth-enabled pediatric RPM, especially during the COVID-19 pandemic, necessitating evidence synthesis. To this end, we conducted a scoping review of clinical trials that had utilized mHealth-enabled RPM of pediatric asthma. MEDLINE, Embase and Web of Science were searched from September 1, 2016 through August 31, 2021. Our scoping review identified 25 publications that utilized synchronous and asynchronous mHealth-enabled RPM in pediatric asthma, either involving mobile applications or via individual devices. The last three years has seen the development of evidence-based, multidisciplinary, and participatory mHealth interventions. The quality of the studies has been improving, such that 40% of included studies reported were randomized controlled trials. In conclusion, there exists high-quality evidence on mHealth-enabled RPM in pediatric asthma, warranting future systematic reviews and/or meta-analyses of the benefits of such RPM.

Abbreviations

BPDBronchopulmonary dysplasiaCFCystic FibrosisCOVID-19Coronavirus Disease 2019mHealthMobile HealthRDSRespiratory Distress SyndromeRPMRemote Patient Monitoring

Keywords

Remote Patient MonitoringmHealthRemote Sensing TechnologyPediatricsBronchial asthmaCOVID-19Respiratory Tract Diseases

Introduction

Digital health interventions have increasingly been permeating into patient care, enabling the development of novel healthcare concepts, including in the field of remote patient monitoring (RPM). Mobile (m) Health is part of the aforementioned digital health interventions. Drawing from capacities of mobile and wireless digital technologies, mHealth supports the transfer of the concepts of patient care, public health, disease management, and health education to patients’ homes, or places of study or work. When mHealth technology is combined with portable (wearable, implantable, etc) digital sensors, it enables RPM in the patients’ habitual environment. Most frequently, RPM via mHealth technologies involves the use of smartphones and specialized mobile apps but can also be carried out through standalone wireless devices. This RPM can be asynchronous (that is, when a medical practitioner checks patient’s health data at time points different from collection) or synchronous (i.e., a real-time remote observation of patient health data)[1], [2], [3].

Implementation of mHealth monitoring in a pediatric setting provides specific challenges, including reliance on support from a parent or caregiver, difficulty of RPM during schooltime, and requirements to the software and hardware to be tailored to the appropriate age groups. In addition, it has been a common recent trend that development of novel technological advancements outpaces the appropriate clinical testing[4]. Moreover, these fast-paced developments have been accelerated during the ongoing COVID-19 pandemic. All this justified conducting a comprehensive synthesis of the recently published evidence on mHealth monitoring in the pediatric respiratory disease. As the first step towards this objective, this scoping review aggregated and synthesized the recent available evidence of mHealth monitoring in pediatric asthma, including during the time of COVID-19 pandemic.

Materials and Methods

Objectives of the scoping review

Primary objectives:

We pursued the following primary objectives. The first primary objective was to obtain an overview of relative abundance of publications on mHealth monitoring in common respiratory diseases in the pediatric population. The second primary objective was to aggregate the published data on synchronous and asynchronous monitoring, be it RPM involving mHealth apps or via standalone (e.g., Internet-of-Things) devices. The third primary objective was to yield a structured synthesis of mHealth apps tailored to children and adolescents.

Secondary objective:

A secondary objective was to reach an informed decision as to whether a systematic review on the pediatric mHealth is warranted by the quantity and quality of the available evidence. We were interested to know which disease or medical condition a future systematic review should cover, and whether there are clinical trials of sufficient quality for critical appraisal of evidence of the benefits of mHealth-enabled RPM.

Pilot MEDLINE search

Towards the first primary objective, we wished to gauge the number of publications for common chronic pediatric respiratory diseases that would be identified by our search strategies (see below). Depending on the number of potential hits, a combined scoping review on several chronic respiratory diseases could be carried out, or the scoping review would focus on pediatric respiratory disease with the most hits. The latter was presumed to be pediatric asthma. The other common chronic pediatric respiratory diseases and conditions were bronchopulmonary dysplasia, cystic fibrosis and bronchiectasis, malformations (e.g., congenital cystic adenomatoid malformation, congenital diaphragmatic hernia, tracheomalacia, or tracheal stenosis), non-cystic fibrosis genetic diseases (e.g., alpha₁-antitrypsin deficiency, sickle cell anemia, ciliary dyskinesia, Duchenne muscular dystrophy), and home ventilation and neonatal respiratory distress syndrome. In addition, we also wished to conduct a search on mHealth monitoring in pediatric COVID-19.

The post A scoping review of mHealth monitoring of pediatric bronchial asthma before and during the COVID-19 pandemic appeared first on mTelehealth.

ASX ANNOUNCEMENT
23 December 2021

Respiri enters its first 5 year Remote Patient Monitoring (RPM) Distribution/Marketing Agreement in the United States with mTelehealth, LLC
Highlights:
• Five-year, Non-Exclusive Distribution and Marketing Agreement signed with mTelehealth in the key US
market
• mTelehealth is a premier provider of RPM services based in Florida
• First key distribution and marketing agreement signed in the US market
• Initial US$150,000 order, with minimum forecast sales of US$1 million over the life of the agreement by mTelehealth
• Physicians will be able to claim RPM CPT reimbursement for wheezo® and Respiri will share these monthly recurring revenues in addition to the devices sales
• Further third party agreements anticipated as Respiri builds out US RPM strategy for wheezo®

Respiri Limited (ASX:RSH)(“Respiri” or the “Company”), an eHealth SaaS Company supporting respiratory health management is excited to announce its first non-exclusive distribution/marketing partnership with Remote Patient Monitoring (RPM) and chronic care provider mTelehealth LLC, effective immediately. Under the terms of the Agreement, mTelehealth has placed a significant initial order for wheezo® devices and services, totalling USD$150,000 in December 2021 for delivery in January 2022 and is contracted to . Either party can terminate with 30 days’ notice if there has been a material breach of the Agreement. This Agreement is material, as the Company currently has no US sales for wheezo®. mTelehealth has forecast a minimum of US$1 million in wheezo® device sales over the five years of the Agreement (forecast only) with a contracted minimum quarterly commitment of 1,000
wheezo® units.

In addition to these initial device sales, Respiri and mTelehealth will share the Product as a Service (PaaS) monthly fees that will be charged to physicians and other Healthcare Professionals claiming RPM and other CPT reimbursement codes.

mTelehealth is a well-respected and known provider of complete turnkey RPM and associated services to physicians and relevant healthcare delivery organisations for over 11 years and is domiciled in Florida, US. mTelehealth’s US footprint is broad and includes the Departments of Health and their County affiliates, payor Health Maintenance Organisations (HMOs), hospitals, Universities, Medical Centres, along with other RPM corporations and institutions. RPM is the use of digital technologies deployed in the collection and analysis of patient physiologic data that are used to develop and manage a treatment plan related to a chronic and/or acute health illness or condition. RPM systems improve patient health and device compliance, which leads to a reduction in hospital admissions and reduced healthcare costs. In parallel, RPM generates new revenue streams for healthcare providers while improving patient care and associated medical information outside the clinic for evaluation and management purposes. In the US, the physician and relevant healthcare physicians are reimbursed directly for providing medical devices to
patients allowing them to provide Remote Patient Monitoring services, which are reimbursed by HMOs and Medicare. Organisations like mTelehealth have built relationships with physicians and relevant medical and reimbursement institutions to deliver devices and services that enable the physician to provide said RPM service enabling them to claim the reimbursement. Respiri has developed a US commercialisation strategy around forging strategic partnerships with such RPM service providers with these existing relationships. The US market is large and fragmented and there is no single company providing national coverage, hence Respiri’s strategy is to execute further agreements to gain broader coverage in the market. Respiri is delighted to have executed an agreement with mTelehealth, as a premier and first partner of the Company.

The overall RPM market is expected to show annual growth exceeding 30% to 2026 to US$85 billion, driven by the increase in the occurrence of chronic diseases (including asthma), demand for wireless and portable systems, the presence of sophisticated reimbursement structures, and a move to more cost effective medical expenditure.1

CEO and Managing Director of Respiri, Mr Marjan Mikel said “We are particularly excited about our partnership with mTelehealth, a trusted RPM partner to many healthcare delivery organisations and physicians across the United States. Marc and his team very quickly understood what patient benefits wheezo® could provide and imparted invaluable local knowhow to help us better tune our US launch strategy and leverage the existing RPM CPT reimbursement codes available to Respiri. This agreement demonstrates that we are executing on our US strategy.”

President and CEO of mTelehealth, Mr Marc Poulshock said “We have a long pedigree in providing our customers across the United States with chronic care and remote patient monitoring turnkey solutions and we could see the health benefits that wheezo® could provide patients with asthma where very little, in the form of RPM solutions are available today. Part of our wheezo® due diligence was to discuss the device with physicians, HMOs and local Department of Health authorities and the responses were very positive. This was again reflected in the high level of inquiry that our initial marketing campaign waves generated from very large HMOs to county health departments and we are very confident with our 5 year forecasts for wheezo® sales. There is definitely a need for wheezo® in the US and we are pleased to have partnered with Respiri in this large and growing market.”

The Company is in active discussions with a number of additional RPM/chronic care providers, which should be finalised progressively during 2022.

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Respiri Limited
P: +61 408 462 873

E: marjan@respiri.co

Mr Nicholas Smedley

Executive Chairman

Respiri Limited

P: +61 447 074 160
E: nicholas@respiri.co

This ASX announcement dated 23 December 2021 has been authorised for release by the Board of Directors of Respiri Limited.

About Respiri Limited

Respiri is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo®, Respiri’s innovative technology, comprises an eHealth app combined with a simple, easy-to-use, handheld device. wheezo® is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians, and other health care professionals.

1 https://www.businesswire.com/news/home/20210720005704/en/85-Bn-Remote-Patient-Monitoring-Market—Global-Forecasts-from-2021-to-2026—
ResearchAndMarkets.com

Respiri’s mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respiri Limited’s operations are based in Melbourne, Australia.

For additional information about Respiri and its products, please visit www.respiri.co

About wheezo®
Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo® device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

For further information about wheezo®, follow the online link https://wheezo.com

wheezo® is a registered trademark of Respiri Limited.

About mTelehealth

mTelehealth, LLC, founded in 2010 and based in Delray Beach, FL, United States, is a premier provider of Remote Patient Monitoring (RPM), Remote Therapeutic Monitoring (RTM), Telemedicine, Chronic Care Management (CCM), Virtual Exam, Video Visit, and related Telehealth solutions. mTelehealth’s Remote Health Monitoring System, Powered by a TouchAway™, provides a complete solution to remotely collect, store, and report timely and accurate health information anywhere. The company connect patients with their families and care providers through an easy-to-use, affordable, remote health monitoring kit. For more information about mTelehealth, please visit our website: https://mtelehealth.com.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respiri current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respiri only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

The post Respiri enters its first 5 year Remote Patient Monitoring (RPM) Distribution/Marketing Agreement in the United States with mTelehealth, LLC appeared first on mTelehealth.

The e-health company’s shares closed in the green today on news of a new partnership

Published December 23, 4:39pm AEDT

The Respiri Ltd (ASX: RSH) share price leapt 14% to 6.5 cents in early trading this morning. This came following the announcement of a distribution and marketing deal with a United States healthcare company.

At the closing bell, Respiri shares had wiggled back down to 5.9 cents apiece, a 3.5% increase from yesterday’s closing price.

Respiri’s telehealth deal

At its core, Respiri is focused on bringing simple respiratory solutions to those living with asthma.

Its primary product, wheezo, assists in the tracking and management of asthmatic symptoms. It also has the ability to share relevant information with doctors and caregivers.

The deal driving the Respiri share price today combines the efforts of US-based remote patient monitoring (RPM) provider mTelehealth, LLC with Respiri.

The partnership entails an initial request from mTelehealth for USD$150,000 (A$208,000) worth of wheezo devices and services to be delivered as early as next month.

Up until now, wheezo products had not been sold in the US.

Respiri also predicts the RPM market will grow by more than 30% by 2026, up to US$85 billion, due to the increase in asthma and chronic diseases.

Therefore, mTelehealth has predicted US$1 million in wheezo sales over the next five years and has agreed to obtain a minimum of 1,000 units every quarter.

This marks the first deal of its kind signed for Respiri.

Respiri CEO pleased with the partnership

Commenting on the news fuelling the Respiri share price today, CEO and managing director Marjan Mikel said:

We are particularly excited about our partnership with mTelehealth, a trusted RPM partner to many healthcare delivery organisations and physicians across the United States.

Marc [Poulshock, president and CEO of mTelehealth] and his team very quickly understood what patient benefits wheezo could provide and imparted invaluable local knowhow to help us better tune our US launch strategy and leverage the existing RPM CPT reimbursement codes available to Respiri.

Poulshock said there was “definitely a need for wheezo in the US” and the company was pleased to have entered the partnership.

Respiri share price snapshot

The Respiri share price has seen a year in red, declining by around 55%.

The company has a market capitalisation of $41.2 million based on its current share price and over 720 million shares issued.

The post Here’s why the Respiri (ASX:RSH) share price jumped 14% today appeared first on mTelehealth.

Markets Reporter

jessica.defreitas@themarketherald.com.au

23 December 2021 14:54 (AEDT)

Respiri (RSH) has entered a non-exclusive distribution and marketing partnership with remote patient monitoring (RPM) and chronic care provider, mTelehealth.

Under the deal, the US-based healthcare company will place an order for Respiri’s wheezo devices and services.

Importantly for Respiri, this marks its first key distribution and marketing deal in the US market.

The wheezo device analyses breath sounds and the eHealth app helps patients with managing their asthma by tracking symptoms, triggers, medicine use and weather conditions.

wheezo is available in pharmacies across Australia and received the tick of approval from the US Food and Drug Administration earlier this year.

Respiri has been focused on commercialising its product in the US market and forming partnerships with Remote Patient Monitoring (RPM) service providers and was pleased to be signing the agreement.

Respiri and mTelehealth will share the Product as a Service (PaaS) monthly fees that will be charged to physicians and other Healthcare Professionals claiming RPM and other Current Procedural Terminology (CPT) reimbursement codes.

Respiri CEO and Managing Director Marjan Mikel is excited about the partnership, praising mTelehealth CEO Marc Poulshock and his team.

“Marc and his team very quickly understood what patient benefits wheezo could provide and imparted invaluable local knowhow to help us better tune our US launch strategy and leverage the existing RPM CPT reimbursement codes available to Respiri. This agreement demonstrates that we are executing on our US strategy.”

The initial order is valued at US$150,000 (A$208,087) however mTelehealth has forecast at least US$1 million (A$1.4 million) in wheezo device sales over the five year term of the agreement. The deal has a contracted minimum quarterly commitments of 1000 wheezo units.

In addition to the initial device sales, Respiri and mTelehealth will share the product-as-a-service monthly fees that will be charged to physicians and other health professionals who claim RPM and other CPT reimbursement codes.

The devices are expected to be delivered in January.

Company shares were up 3.51 per cent and trading at 5.9 cents at 2:11 pm AEDT.

The post Respiri (ASX:RSH) enters US distribution deal with mTelehealth appeared first on mTelehealth.

The post wheezo – Digital Wheeze Monitor – Owner’s Manual appeared first on mTelehealth.